States shying away from administering Bharat Bio's Covid-19 vaccine Covaxin

A month on, 21 states and UTs have not administered a single shot of the vaccine

States shying away from administering Bharat Bio’s Covid-19 vaccine Covaxin
States like West Bengal have given only 720 doses of Covaxin to beneficiaries as on February 9. Uttar Pradesh has used the most number of Covishield doses – 664,084
Sohini Das Mumbai
3 min read Last Updated : Feb 18 2021 | 6:10 AM IST
A month into the Covid-19 immunisation drive, as many as 21 states and Union Territories (UTs) have not administered a single shot of Covaxin from Bharat Biotech, according to data. 

While some states like Chhattisgarh have opted not to use the Covaxin doses allotted to them, most UTs and northeastern states have not been allotted the vaccine by the Centre. For those that have used Covaxin, the rate of usage is much lower compared to the number of Covishield vaccines used.

Gujarat administered the maximum number of Covaxin shots in the first round – 106,043 doses were given to beneficiaries in the state. States like West Bengal have given only 720 doses of Covaxin to beneficiaries as on February 9. Uttar Pradesh has used the most number of Covishield doses – 664,084. This information has been culled from data shared by the Union health ministry with the Lok Sabha.  

Many states like Chattisgarh, Goa, Ker­ala, the north-eastern states of Manipur, Meghalaya, Arunachal Pradesh, Mizoram, Nagaland, Tripura and Sikkim, along with Uttarakhand, are among those that have not used a single dose of Covaxin. 


Also, UTs like Ladakh, Chandi­garh, Daman & Diu as well as Dadra and Nagar Haveli have also not used the ind­igenous vaccine but the AstraZeneca vaccine Covishield. States such as Chatt­isgarh and UTs like Chandi­garh had indicated in January that they were not comfortable with using Covaxin on their health care and frontline workers until complete data on efficacy of the vaccine was available. 

However, of the 23 deaths reported in people post-immunisation, most had taken the Covishield jab. The government has maintained that none of the deaths have been causally linked to Covid-19 vaccination and highlighted that both vaccines are ‘safe’. According to data released by the government last week, the percentage of deaths is as low as 0.0003 per cent. 

States did not have much of a choice when it came to picking one vaccine over the other. A senior government official in Gujarat said, “We were not given a choice. We were told how many doses of which vaccine we were getting from the Centre. We had to plan our vaccination sites acco­rdingly as each site would have only one type of vaccine for logistical purposes.” On the other hand, some states like Chatt­isgarh had categorically said they were not in favour of using Covaxin in clinical trials. 

IndiaSpend highlighted, in an article, that India administered the Covid-19 vaccine to 8.4 million people (as on February 15) in one month since launching the world’s largest vaccination programme on January 16. 

“At this rate per month, India is likely to miss its target of vaccinating 250 million people by July,” the author, Anoo Bhuyan, said in the piece. In comparison, the US already vaccinated 52.8 million, UK around 15.6 million and China around 40.5 million.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineBharat BiotechPharma CompaniesHealth sectorHealth Ministry

Next Story